ABOUT EUROPEAN VACCINE MANUFACTURES
EVM mission
To create a supportive environment for improved vaccine protection and coverage in the interest of individuals and the community. To promote vaccine R & D to meet new challenges for innovative vaccine applications against infectious and other types of diseases. To foster a favourable policy climate for the vaccine industry in Europe to bring new vaccines to the world.
EVM structure
EVM is governed by a General Assembly, meeting once a year, that comprises two representatives of each member company ; and an EVM Board, elected by the General Assembly, that defines EVM strategy and policies in line with EFPIA policies.
EVM Board
Officers
President - Patrick Florent (GlaxoSmithKline Biologicals)
Vice-President - Didier Hoch (Sanofi Pasteur MSD)
Treasurer - Mike Watson (Sanofi Pasteur)
Members
Andrew Ferguson (Crucell)
Alexandra Fischer (AstraZeneca)
Bernard Fritzell (Pfizer)
Karen Huebscher (Novartis Vaccines)
Sjirk Kok (Abbott Biologicals)
Silvia Steyrer-Gruber (Baxter)
Working Group Chairpersons
Sian Clayden (GlaxoSmithKline Biologicals) - Chair of External Affairs working group
Stephen Gardner (GlaxoSmithKline Biologicals) - Chair of Influenza Working Group
Bernadette Hendrickx (Sanofi Pasteur) - Chair of Regulatory & Scientific Working Group
Serge Montero (Sanofi Pasteur MSD) - Chair of National Vaccine Industry Coordination Working Group
Christine Seigneur (Sanofi Pasteur MSD) - Chair of Market Access Working Group
EVM Working Groups
>> Regulatory & Scientific Affairs
Europe is at the heart of the global vaccine industry. Did you know that the EVM members :
- are the largest supplier of vaccines in the world, producing the majority of vaccine doses in Europe
- Have the majority of their manufacturing and R&D production facilities in Europe but, as global companies, they also have sites across the globe through international collaboration and joint ventures
- Supply vaccines to developing countries through humanitarian groups and supranational organizations, such as UNICEF and through public-private partnerships, such as GAVI
- are working in collaboration with the public sector in joint R&D activities and in clinical trials partnerships to develop vaccines against diseases that particularly burden developing countries (e.g., dengue fever, leishmaniasis, rotavirus, HIV, malaria and tuberculosis, among others)
- contribute significantly to Research & Development with over half of all global vaccine R&D being carried out in Europe
- Support Europe’s knowledge-economy and provide high-skilled employment
- Develop and produce new innovative vaccines, with major potential for Public Health worldwide